Martin Comtesse, an analyst from Jefferies, maintained the Buy rating on Redcare Pharmacy. The associated price target remains the same with €150.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Martin Comtesse has given his Buy rating due to a combination of factors that suggest a positive outlook for Redcare Pharmacy. The company has shown a significant improvement in prescription sales in the third quarter, reversing the declining trend observed in the previous two quarters. This rebound in sales, with a notable increase to €12 million quarter-over-quarter, indicates a potential turning point for the company.
Moreover, management’s confirmation of fiscal year 2025 targets for all key performance indicators, along with expectations for a stronger fourth quarter, further supports the optimistic view. The EBITDA margin for the first nine months of 2025 has also remained within the guided range, which is likely to restore market confidence following the unexpected departure of the CFO. These factors collectively underpin the Buy rating given by Martin Comtesse.
According to TipRanks, Comtesse is an analyst with an average return of -3.3% and a 39.42% success rate. Comtesse covers the Technology sector, focusing on stocks such as Bechtle Aktiengesellschaft, CANCOM SE, and Nagarro SE.
In another report released on September 30, Deutsche Bank also maintained a Buy rating on the stock with a €214.00 price target.